Browsing Tag
CB-011
2 posts
Why is Caribou Biosciences ending CAR-T development before a planned phase 3 trial?
Caribou Biosciences is winding down its allogeneic CAR-T programmes and sharply reducing its workforce after financing constraints overtook clinical progress, leaving $113.8 million of mid-year liquidity and its genome-editing assets at the centre of a strategic review.
Caribou Biosciences set for key webcast showcasing CRISPR-engineered CAR-T breakthroughs in blood cancers
Discover how Caribou Biosciences is preparing to reveal breakthrough CRISPR-edited allogeneic CAR-T data in lymphoma and myeloma during its investor webcast.